ZEUS System (Zio Watch) vs Tempus ECG-AF
AI Verdict
Choose ZEUS System (Zio Watch) if…
Choose the ZEUS System (Zio Watch) if you require long-term, continuous cardiac monitoring to detect and characterize existing or suspected atrial fibrillation (AFib) and other arrhythmias over an extended period. This wearable solution is ideal for patients needing up to 14 days of monitoring, offering comprehensive data collection and actionable insights for physicians, complemented by a patient app for symptom logging.
View ZEUS System (Zio Watch) →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation/flutter within the next 12 months, based on a standard 12-lead ECG. This AI-based algorithm is best suited for proactive risk stratification in an asymptomatic population without pre-existing AF, supporting earlier identification and follow-up care.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ZEUS System (Zio Watch) | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact vendor | Contact vendor |
| Deployment | Cloud-based system with a wearable device | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS System (Zio Watch)Tool A, the ZEUS System, offers a patient-facing wearable (Zio Watch) and a MyZio patient app, alongside provider portals and mobile apps. This comprehensive approach provides a more direct and continuous user experience for both patients and clinicians compared to Tool B's software-only solution for existing ECGs.
Clinical Value
ZEUS System (Zio Watch)Tool A provides long-term continuous monitoring for up to 14 days, directly detecting and characterizing Atrial Fibrillation (AFib) and other cardiac arrhythmias, offering immediate diagnostic and management insights. While Tool B offers valuable predictive risk assessment for future AF, Tool A's capability for direct, continuous diagnosis and characterization of current arrhythmias provides more immediate clinical utility for active patient management.
Pricing & Value
Tempus ECG-AFTool B explicitly details CMS reimbursement availability with specific CPT codes and a Medicare rate, providing clear financial transparency and a pathway for value realization for healthcare providers. Tool A only states 'contact vendor' for pricing, offering no comparable information on reimbursement or cost structure.
Enterprise Readiness
Tempus ECG-AFBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, indicating a strong foundation for enterprise use. However, Tool B is a software solution designed to integrate with existing 12-lead ECG systems from major vendors like GE and Philips, potentially offering a smoother and less logistically complex deployment within established healthcare facility systems compared to Tool A's requirement for managing a new wearable device ecosystem.
Innovation
ZEUS System (Zio Watch)Tool A demonstrates significant innovation by combining an AI-powered wearable biosensor for continuous ECG and PPG data collection with long-term monitoring capabilities (up to 14 days). This approach pushes the boundaries of remote, real-world data acquisition for cardiac arrhythmia detection. While Tool B innovatively applies AI to existing 12-lead ECGs for risk prediction, Tool A's integration of advanced wearable technology for extended, continuous monitoring represents a more transformative step in data collection and patient engagement for cardiac health.
Support & Docs
TieNeither the provided structured facts nor general web searches offer sufficient specific details regarding dedicated customer support channels, technical documentation, or training programs to differentiate between the two tools. Both mention patient and provider-facing applications for managing data and reports, but these are product features rather than explicit support and documentation offerings.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ZEUS System (Zio Watch) | Tempus ECG-AF |
|---|---|---|
| Tool Name | ZEUS System (Zio Watch) | Tempus ECG-AF |
| Company | iRhythm Technologies | Tempus AI, Inc. |
| Primary Detection Target | Detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias | Identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months |
| Monitoring/Analysis Type | Long-term continuous cardiac monitoring (ECG and PPG data collection) | AI-based algorithm analyzes 12-lead ECG recordings |
| Target Patient Population | Not specified | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery |
Videos
Demos, reviews, and walkthroughs featuring ZEUS System (Zio Watch) and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring ZEUS System (Zio Watch) or Tempus ECG-AF
Backers
Who funded each tool's parent company.